Title
|
Phase
|
Protocol IDs
|
| ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen |
Phase III
|
ALFACELL-P30-302
NCT00003034, NCI-V97-1273
|
| Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma |
Phase III
|
CRC-BOC-L52
EU-20033, NCT00006231
|
| Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma |
Phase III
|
BTS-MRC-MS01
EU-20349, ISRCTN54469112, NCT00075699
|
| Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer |
Phase III
|
FCCC-FCRB-04-002-P
NCT00372840
|
| Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma |
Phase II
|
BC-MA-2
NCT00003508
|
| Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer |
Phase II
|
SVMC-ONC-222
NCT00002475, NCI-V91-0075
|
| Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma |
Phase II
|
RPCI-RP-9812
NCT00054002
|
| Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma |
Phase II
|
ECOG-E1B03
NCT00101283, NCCTG-E1B03
|
| Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
Phase II
|
SP-14-0038
NCT00123773
|
| Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
Phase II
|
EORTC-08031
EudraCT-2004-004273-28, NCT00227630
|
| AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery |
Phase II
|
SWOG-S0509
NCT00243074
|
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma |
Phase II
|
03-369
NCT00137826
|
| Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma |
Phase II
|
8848
NCT00192010, H3E-IT-S079
|
| AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery |
Phase II
|
UCCRC-14203B
NCT00309946, NCI-7103
|
| A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
Phase II
|
SP-14-0039
NCT00271648
|
| Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma |
Phase II
|
AVF3442S
NCT00295503
|
| Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
Phase II
|
SWS-SAKK-17/04
EU-20615, EUDRACT-2006-000445-19, LILLY-SAKK-17/04, NCT00334594
|
| Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma |
Phase II
|
CASE-CCF-IRB-5179
CASE-CCF-0755, NCT00354393
|
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery |
Phase II
|
CCC-PHII-67
NCT00365053, NCI-7255
|
| Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma |
Phase II
|
CAN-NCIC-IND.183
NCT00392444
|
| Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases |
Phase I
|
NCI-02-C-0205J
NCT00037817, NCI-5270
|
| Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies |
Phase I
|
DFCI-03082
NCT00070239, NCI-6052
|
| FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer |
Phase I
|
NCI-05-C-0010
NCT00094978, NCI-5987
|
| Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors |
Phase I
|
2005_006
NCT00106626
|
| Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors |
Phase I
|
CA225-101
NCT00207077
|
| Gene Therapy for Pleural Malignancies |
Phase I
|
803776
NCT00299962, UPCC 03505
|
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) |
Phase I
|
CS1008-A-U101
NCT00320827
|
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer |
Phase I
|
MORAb-009-001
NCT00325494
|
| A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors |
Phase I
|
CA187-002
NCT00329004
|
| A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer |
Phase I
|
CA165-030
NCT00332748
|
| Monoclonal Antibody MORAb-009 in Treating Patients With Recurrent Advanced Tumors That Express Mesothelin |
Phase I
|
NCI-06-C-0196
MORAb-009-001, NCI-P6942, NCT00325494
|
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma |
Phase I
|
MSKCC-06085
NCT00398138
|
| EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer |
No phase specified
|
UPCC-05901
NCI-4110, UPCC-IRB-702341, NCT00028782
|
| Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery |
No phase specified
|
ICR-CTSU-MARS
EU-20532, NCT00253409
|
| Biobank Sarcoma: Storing Blood for Analysis of DNA and Protein of Patients With Sarcoma |
No phase specified
|
P04.0954L
NCT00181480
|
| Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers |
No phase specified
|
Asbestos Screening Study
NCT00188890
|
| Multiple Biomarkers in Undiagnosed Pleural Effusion |
No phase specified
|
FDI-02 Pleural Effusion Study
NCT00316134
|
Home Page